Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

Miles David; Cameron David; Bondarenko Igor; Manzyuk Lyudmila; Alcedo Juan Carlos; Lopez Roberto Ivan; Im Seock-Ah; Canon Jean-Luc; Shparyk Yaroslav; Yardley Denise A.; Masuda Norikazu; Ro Jungsil; Denduluri Neelima; Hubeaux Stanislas; Quah Cheng; Bais Carlos; OShaughnessy Joyce

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

【24h】

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

机译：Bevacizumab Plus Paclitaxel与安慰剂加上紫杉醇作为Her2阴性转移性乳腺癌（Meridian）的一线疗法：双盲安慰剂随机期III试验，具有前瞻性生物标志物评估

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aim: MERiDiAN evaluated plasma vascular endothelial growth factor-A (pVEGF-A) prospectively as a predictive biomarker for bevacizumab efficacy in metastatic breast cancer (mBC).

机译：目的：经络评估血浆血管内皮生长因子-A（PVEGF-A）作为转移乳腺癌（MBC）中的北伐单抗疗效的预测生物标志物。

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2017年第2017期|共10页
作者
Miles David; Cameron David; Bondarenko Igor; Manzyuk Lyudmila; Alcedo Juan Carlos; Lopez Roberto Ivan; Im Seock-Ah; Canon Jean-Luc; Shparyk Yaroslav; Yardley Denise A.; Masuda Norikazu; Ro Jungsil; Denduluri Neelima; Hubeaux Stanislas; Quah Cheng; Bais Carlos; OShaughnessy Joyce;
展开▼
作者单位

Mt Vernon Canc Ctr Rickmansworth Rd London HA6 2RN England;

Univ Edinburgh Crewe Rd South Edinburgh EH4 2XU Midlothian Scotland;

Multiprofile Clin Hosp Dnipropetrovsk Med Acad Dept Oncol 449102 Blizhnaya Str Dnepropetrovsk;

NN Blokhin Canc Ctr Kashirskoye Schosse 23 Moscow 115478 Russia;

Marbella Edificio Royal Ctr Ctr Hemato Oncol Panama 5to Piso Torre B Panama City Panama;

Natl Oncol Inst Dept Med Oncol Gorgas &

Juan de Arco St POB 0816-04433 Panama City Panama;

Seoul Natl Univ Seoul Natl Univ Hosp Coll Med Dept Internal Med Canc Res Inst 101 Daehak Ro;

Grand Hop Charleroi Oncol &

Haematol Serv Grand Rue 3 B-6000 Charleroi Belgium;

Lviv State Oncol Reg Treatment &

Diagnost Ctr 2a Hashek Str UA-79031 Lvov Ukraine;

Sarah Cannon Res Inst 3322 West End Ave Suite 900TN Nashville TN 37203 USA;

Osaka Natl Hosp Natl Hosp Org Dept Surg Breast Oncol Chuou Ku 2-1-14 Hoenzaka Osaka 5400006;

Natl Canc Ctr Ctr Breast Canc 323 Ilsan Ro Goyang Si 10408 Gyeonggi Do South Korea;

US Oncol Virginia Canc Specialists Res Inst 1635 N George Mason Suite 170 Arlington VA 22205 USA;

F Hoffmann La Roche Biostat Oncol Pharma Dev Bldg 670 Malzgasse 30 CH-4070 Basel Switzerland;

Genentech Inc Global Dev BioOncol 1 DNA Way San Francisco CA 94080 USA;

Genentech Inc Global Dev BioOncol 1 DNA Way San Francisco CA 94080 USA;

US Oncol Baylor Charles A Sammons Canc Ctr 3410 Worth St Suite 400 Dallas TX 75246 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Bevacizumab; Metastatic breast cancer; Predictive; Biomarker; Double-blind; VEGF-A; Weekly paclitaxel; Prospective;

机译：Bevacizumab;转移性乳腺癌;预测;生物标志物;双盲;VEGF-A;每周紫杉醇;潜在的;

相似文献

外文文献
中文文献

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation [J] . Miles David, Cameron David, Bondarenko Igor, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：Bevacizumab Plus Paclitaxel与安慰剂加上紫杉醇作为Her2阴性转移性乳腺癌（Meridian）的一线疗法：双盲安慰剂随机期III试验，具有前瞻性生物标志物评估
3. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triplenegative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (vol 18, pg 1360, 2017) [J] . Kim S. B., Dent R., Im S. A. The lancet oncology . 2018,第12期

机译：Ipatasertib plus paclitaxel与安慰剂加上紫杉醇作为转移性三重乳腺癌的一线治疗（莲花）：多期，随机，双盲，安慰剂控制，第2期试验（Vol 18，Pg 1360,2017）
4. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial [J] . Kim Sung-Bae, Dent Rebecca, Im Seock-Ah, The lancet oncology . 2017,第10期

机译：Ipatasertib Plus Paclitaxel与安慰剂加上紫杉醇作为转移性三重阴性乳腺癌的一线治疗（莲花）：多方形，随机，双盲，安慰剂控制，第2期试验
5. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
6. Cost-Benefit Analysis of Nanoparticle Albumin-Bound Paclitaxel versus Solvent-Based Paclitaxel for the Treatment of Metastatic Breast Cancer in the United States [D] . Vichansavakul, Kittaya 2013

机译：纳米白蛋白结合紫杉醇与溶剂型紫杉醇在美国治疗转移性乳腺癌的成本效益分析
7. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre randomised double-blind placebo-controlled phase 2 trial [O] . Prof Sung-Bae Kim, Rebecca Dent, Seock-Ah Im, -1

机译：Ipatasertib加紫杉醇与安慰剂加紫杉醇作为转移性三阴性乳腺癌（LOTUS）的一线治疗：一项多中心随机双盲安慰剂对照的2期试验
8. Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’ [O] . C. De Angelis, D. Bruzzese, A. Bernardo, 2021

机译：勘探为“二林蛋白与Bevacizumab相结合，作为HER2阴性转移性乳腺癌的二线治疗，与紫杉醇和Bevacizumab具有一线治疗后进展：多中心，II期，单臂试验（GIM11-Bergi）'

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

摘要

著录项

相似文献

相关主题

期刊订阅